Allarity Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLR research report →
Price Chart
About the company
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics.
- CEO
- Thomas H. Jensen
- IPO
- 2021
- Employees
- 8
- HQ
- Tarpon Springs, FL, US
Get TickerSpark's AI analysis on ALLR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.56M
- P/E
- -0.88
- PEG
- -0.07
- P/S
- 39.54
- P/B
- -6.09
- EV/EBITDA
- -1.70
- Div Yield
- 0.00%
- Gross Margin
- 98.29%
- Op Margin
- -3938.29%
- Net Margin
- -4493.71%
- ROE
- -349.08%
- ROIC
- -66.41%
Latest fiscal year · YoY change
- Revenue
- $320.00K+0.0%
- Gross Profit
- $320.00K+0.0%
- Op Income
- $-12,605,000
- Net Income
- $-11,231,000+54.2%
- EPS
- $-0.78+95.1%
- OCF Growth
- +14.6%
- FCF Growth
- +16.0%
- 52W High
- $1.84
- 52W Low
- $0.77
- 50D MA
- $0.98
- 200D MA
- $1.21
- Beta
- 0.57
- RSI (14)
- 37
- Avg Volume
- 128.71K
No earnings-call transcripts are available for ALLR yet.
- Free Float
- 76.3%
- Shares Outstanding
- 16.00M
- Float Shares
- 12.20M
of shares held by institutions
8 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 6 ETFs
Biggest fund positions in ALLR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Graff Jeremy R. | other | 39,494 |
| Jan 22, 26 | Graff Jeremy R. | other | 48,147 |
| Sep 30, 26 | Graff Jeremy R. | other | 39,494 |
| Sep 30, 26 | Graff Jeremy R. | other | 14,613 |
| Jan 22, 26 | Graff Jeremy R. | other | 48,147 |
| Jan 22, 26 | Graff Jeremy R. | other | 17,814 |
| Jan 28, 26 | Jensen Thomas | other | 200,000 |
| Jan 7, 26 | Hoeiland Jesper | other | 25,000 |
| Jun 10, 25 | Hoeiland Jesper | other | 0 |
| Jan 28, 26 | McLaughlin Gerald W. | other | 45,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALLR coverage
Recent articles, reports, and earnings notes.
No research on ALLR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALLR report →Allarity Therapeutics Granted U.S. Patent for Stenoparib's Clinical Dosing Regimen, with Protection Into 2045
globenewswire.com · Nov 18
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
globenewswire.com · Nov 16
Allarity Therapeutics (NASDAQ:ALLR) Releases Earnings Results, Misses Expectations By $0.18 EPS
defenseworld.net · Nov 15
Allarity Therapeutics (NASDAQ:ALLR) Releases Quarterly Earnings Results, Misses Expectations By $0.18 EPS
defenseworld.net · Nov 15
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
globenewswire.com · Nov 13
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
globenewswire.com · Oct 30
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
zacks.com · Oct 9
Critical Review: Evogene (NASDAQ:EVGN) vs. Allarity Therapeutics (NASDAQ:ALLR)
defenseworld.net · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.